On August 10, 2023, the Company entered into a binding term sheet with Hanmi Pharmaceuticals Co., Ltd. (“Hanmi”) whereby Hanmi agreed at their sole discretion to invest over a time period ending June 30, 2024, up to a maximum of $7 million in Aptose up to a total ownership of 19.99 percent of Aptose by Hanmi (Hanmi currently holds 215,703 shares of Aptose). The deal is subject to completion of definitive documentation and customary closing conditions. The Company shall use the proceeds from this investment solely for tuspetinib-related business operations purposes. The Company currently has a licensing agreement with Hanmi for tuspetinib which was entered into on November 4, 2021. In 2022 the Company and Hanmi also entered into a separate supply agreement for additional production of new drug substance ("API") and drug product to support further tuspetinib clinical development for which the Company pays Hanmi per batch of production. The tuspetinib licensing agreement with Hanmi requires the Company to make milestone payments based on progression of research as outlined in Note 13 to the annual financial statements. The Company anticipates that $3 million will be invested by the end of August 2023, subject to the satisfaction of customary closing conditions. The second investment of up to $4 million or a maximum of 19.99 percent ownership interest in the Company by Hanmi is contingent on Aptose meeting certain manufacturing and data milestones related to tuspetinib by June 30, 2024 and anticipated to be achieved by year-end.

Subsequent to June 30, 2023, the Company issued 127,344 shares under the 2022 ATM Facility at an average price of $4.39 for gross proceeds of $559 thousand ($542 thousand net of share issuance costs). On a cumulative basis to August 10, 2023, the Company has issued 303,433 shares under the 2022 ATM Facility at an average price of $5.90 for gross proceeds of $1.79 million ($1.74 million net of share issue costs). Costs associated with the proceeds consisted of 3% cash commission.

Subsequent to June 30, 2023, the Company sold 11,421 shares to Keystone under the Keystone Equity Facility for net proceeds of $50,000.

Subsequent to June 30, 2023, the Company issued 4,453 shares under the ESPP.